Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Sponsor: Fudan University